Psilocybin (COMP360) vs VLS-01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
Psilocybin (COMP360)
Developed by COMPASS Pathways
NCT05711940 · Phase 3 · active, not recruiting
This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2029 · NCT06132178 (registry estimate)
Reported efficacy
COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. (Week 6): COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. (met)
Result source: NCT05711940
VLS-01
Developed by AtaiBeckley Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Psilocybin (COMP360) | VLS-01 |
|---|---|---|
| MADRS, change (acute) | -12 vs -6.8−5.2 vs placeboNCT03775200 | —Not reported |
| CGI-S, change (acute) | —Not posted · NCT05624268 | —Not reported |
| MADRS response | —Not posted · NCT05624268 | —Not reported |
| MADRS remission | —Not posted · NCT05624268 | —Not reported |
| Relapse (% of patients) | —Not posted · NCT05624268 | —Not reported |
MADRS, change (acute)
- Psilocybin (COMP360)
- -12 vs -6.8−5.2 vs placeboNCT03775200
- VLS-01
- —Not reported
CGI-S, change (acute)
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- VLS-01
- —Not reported
MADRS response
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- VLS-01
- —Not reported
MADRS remission
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- VLS-01
- —Not reported
Relapse (% of patients)
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- VLS-01
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
VLS-01: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Psilocybin (COMP360): 3 of 4 rows · VLS-01: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Psilocybin (COMP360) |
|---|---|
| Dropout rate | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result—25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mga headache 31.6% blood pressure increased 15.8% depression 5.3% NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result25 mg headache 34.2% (placebo 25.3%) nausea 22.8% (placebo 5.1%) fatigue 15.2% (placebo 8.9%) NCT03775200 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Psilocybin (COMP360)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Psilocybin (COMP360)'s landscape · VLS-01's landscape